Recent

% | $
Quotes you view appear here for quick access.

Prana Biotechnology Limited Message Board

kadaicher1 284 posts  |  Last Activity: 6 hours ago Member since: Jan 23, 2004
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    So far in the 3D live human AD model.

    by kadaicher1 Jul 21, 2016 5:48 AM
    kadaicher1 kadaicher1 6 hours ago Flag

    No copper, please stop lying. Tanzi has stated he intends to release some results from his work at the AAIC so just sit tight and we are sure to see how PBT2 performed and if he was able to confirm his first results with PBT2.
    "We have been using Alzheimer’s-in-a-Dish to find drugs that will slow or halt plaque and
    tangle formation. Among those that are being tested is PBT2. Studies of PBT2 are still in
    progress and once confirmed, will be submitted for publication. So far, the preliminary
    findings show that PBT2 has the following effects in Alzheimer’s-in-a-Dish: 1. A trend in the
    direction of attenuation of the aggregation and fibrillization of the Abeta peptide into betaamyloid,
    2. significantly reduced tangle formation, and 3. significantly increased cell viability.
    Once these results are confirmed, PBT2 would become the only compound tested in
    Alzheimer’s-in-a-Dish to achieve all three of these effects on AD pathology. "

    And from an unbiased Whitehead Institute mass screening through an AD model in yeast:
    "One group of hit compounds was 8-hydroxyquinolines (8-OHQ), a class of clinically relevant bioactive metal chelators related to clioquinol. Surprisingly, in otherwise wild-type yeast cells, different 8-OHQs had selectivity for rescuing the distinct toxicities caused by the expression of TDP-43, α-synuclein, or polyglutamine proteins. In fact, each 8-OHQ synergized with the other, clearly establishing that they function in different ways. Comparative growth and molecular analyses also revealed that 8-OHQs have distinct metal chelation and ionophore activities. The diverse bioactivity of 8-OHQs indicates that altering different aspects of metal homeostasis and/or metalloprotein activity elicits distinct protective mechanisms against several neurotoxic proteins."

    Synergy means a lot with over 1000 drugs in the library to work with.

    Sentiment: Strong Buy

  • Reply to

    What to watch for at AAIC 2016

    by interesting2me Jul 20, 2016 9:11 AM
    kadaicher1 kadaicher1 6 hours ago Flag

    Bio, it is you who try never stop spouting BS or do you think Prof Adlard was lying?
    [The other hallmark pathological feature of Alzheimer's disease is the presence of neurofibrillary tangles, composed of abnormal tau protein. In his presentation, entitled "Metal Chaperones are novel therapeutic agents for tauopathy', Associate Professor Adlard will present new data showing that treatment with PBT2 significantly improves cognition and reduces the abundance of tau aggregates through metal mediated mechanisms in a transgenic mouse model of tau overexpression.]
    Regarding LMTX" Our findings demonstrate that biologically selective pharmaceutical agents could be developed to facilitate the proteolytic degradation of tau aggregates..." OK that is the "could be" covered, show me the "we did it" in humans. Maybe Tanzi has done it with LMTX or MBlue in his model. There is not long to wait.

    Sentiment: Strong Buy

  • Reply to

    So far in the 3D live human AD model.

    by kadaicher1 Jul 21, 2016 5:48 AM
    kadaicher1 kadaicher1 Jul 22, 2016 7:52 PM Flag

    0users liked this postsusers disliked this posts0Reply
    They have the drug. The reason for the safety data package upgrade is to start the final stage phase3. Your post is worthless waffle as usual. I don't think there is much newer than Tanzi's 3D live human AD neuron model. He has stated he will be reporting results at the conference. Lets just wait and see if PBT2 comes out on top AGAIN.

    Sentiment: Strong Buy

  • kadaicher1 kadaicher1 Jul 22, 2016 7:42 PM Flag

    It is speaking about investors who actually own stock. If this has had a 90% loss, then it represents a possibility of many multiples to get from this level back to the inconclusive pre IMAGINE trial result price.Possible 10 bagger, and that was before results.

    Sentiment: Strong Buy

  • Reply to

    What to watch for at AAIC 2016

    by interesting2me Jul 20, 2016 9:11 AM
    kadaicher1 kadaicher1 Jul 22, 2016 7:36 PM Flag

    If LMTX works it is good news for Prana as PBT2 prevents and clears tangles through just one arm of the PBT2 MOA,
    Intresting TauRx chose ADAS-cog 11 for the primary end point. LLY did the same with the Sola EXPEDITION trials, but changed to ADAS-cog 14 before the data lock and analysis.
    MMSE is a secondary endpoint.
    Interestingly in secondary and other outcomes, they are comparing brain volume measurements with expected decline rate and I guess not placebo.
    [Change in expected decline of whole brain volume as measured by brain MRI [ Time Frame: 78 weeks ]
    Change in expected increase in ventricular volume as measured by brain MRI [ Time Frame: 78 weeks ]
    Change in expected decline in hippocampal volume as measured by brain MRI [ Time Frame: 78 weeks ]

    Sentiment: Strong Buy

  • Reply to

    So far in the 3D live human AD model.

    by kadaicher1 Jul 21, 2016 5:48 AM
    kadaicher1 kadaicher1 Jul 21, 2016 5:57 AM Flag

    [significantly reduced tangle formation,] So PBT2 reduced tau in the live human cell model, just like the animal models.

    Sentiment: Strong Buy

  • [We have been using Alzheimer’s-in-a-Dish to find drugs that will slow or halt plaque and tangle formation. Among those that are being tested is PBT2. Studies of PBT2 are still in progress and once confirmed, will be submitted for publication. So far, the preliminary findings show that PBT2 has the following effects in Alzheimer’s-in-a-Dish:
    1. A trend in the direction of attenuation of the aggregation and fibrillization of the Abeta peptide into beta amyloid,
    2. significantly reduced tangle formation,
    and 3. significantly increased cell viability.
    Once these results are confirmed, PBT2 would become the only compound tested in Alzheimer’s-in-a-Dish to achieve all three of these effects on AD pathology. ]
    Perhaps confirmation at AAIC

    Sentiment: Strong Buy

  • Reply to

    Locked and loaded.

    by kadaicher1 Jul 12, 2016 4:21 AM
    kadaicher1 kadaicher1 Jul 20, 2016 5:15 PM Flag

    Hey ITM, I hope they can resolve this data package in the next few weeks/months. This is starting to get like watching grass grow. Maybe the conference can liven things up some.

    Sentiment: Strong Buy

  • kadaicher1 kadaicher1 Jul 12, 2016 12:20 PM Flag

    Thanks. I can see why they would go there.[ However, zinc is a co-factor of many enzymes and, like lithium, may initiate many cellular effects independently of GSK-3. Still, research with lithium and zinc may further our understanding of the biological functions of GSK-3 in man. Worth mentioning is also the indirect GSK-3 inhibition produced by the inorganic salt sodium tungstate (Gómez-Ramos et al., 2006). As a consequence of the GSK-3 inactivation, the phosphorylation of several GSK-3 dependent sites of the microtubule tau protein decreases (Gómez-Ramos et al., 2006).]
    [Other metal ions such as beryllium, zinc, mercury, and copper are potent GSK-3 inhibitors (Ilouz et al., 2002; Ryves et al., 2002). Interestingly, these cations are more potent inhibitors of GSK-3 than lithium (IC50 in the micromolar concentration range as compared to the IC50 of lithium which is within the millimolar concentration range). Of particular interest is the trace element zinc, that unlike lithium, and other metal ions is naturally found in the body tissues. ]

    Sentiment: Strong Buy

  • kadaicher1 by kadaicher1 Jul 12, 2016 4:21 AM Flag

    Prana missed the original guidance for completion of their data package so the price remains depressed. The start of a phase3 is depending on that safety data completion. Look out when the data is submitted because it is unlikely Prana are doing nothing with their 1000+ drug library. The drugs are metal chaperone compounds with utility throughout the central nervous system including the eyes.

    Sentiment: Strong Buy

  • kadaicher1 kadaicher1 Jul 11, 2016 1:06 PM Flag

    Oops I meant after HD. Sorry if that confused you further.

    Sentiment: Strong Buy

  • Reply to

    Errors here, errors there,.

    by copper725 Jul 10, 2016 7:07 PM
    kadaicher1 kadaicher1 Jul 11, 2016 1:04 PM Flag

    Tanzi published dopey, and it was 2010. You know that or have serious memory problems. Or perhaps ethical problems.

    Sentiment: Strong Buy

  • kadaicher1 kadaicher1 Jul 11, 2016 12:46 PM Flag

    Repeat LMTX is the second drug into trials to target tangles.Good results for LMTX bode well for PBT2 in AD considering PBT2 has yet to be trialled in a properly powered trial for AD, but anyway that is in line for after AD.

    Sentiment: Strong Buy

  • kadaicher1 kadaicher1 Jul 11, 2016 12:37 PM Flag

    Phosphorylation of tau is normal. The breaking down and rebuilding of microtubulins is normal. What is your point.

    Sentiment: Strong Buy

  • Reply to

    Errors here, errors there,.

    by copper725 Jul 10, 2016 7:07 PM
    kadaicher1 kadaicher1 Jul 11, 2016 11:08 AM Flag

    Tanzi was the first to demonstrate the innate immune function about 4 years before the pack. You remember the Prana co founder Tanzi. That is why it is important not to attack AB function directly. PBT2 does not directly attack the AB system. You try to work it out.

    Sentiment: Strong Buy

  • kadaicher1 kadaicher1 Jul 11, 2016 11:02 AM Flag

    I hope the NIH NIA site is a source you can relate to.
    [In AD, an abnormally large number of additional phosphate molecules attach to tau. As a result of this “hyperphosphorylation,” tau disengages from the microtubules and begins to come together with other tau threads. These tau threads form structures called paired helical filaments, which can become enmeshed with one another, forming tangles within the cell. The microtubules can disintegrate in the process, collapsing the neuron’s internal transport network. This collapse damages the ability of neurons to communicate with each other.]
    If that is not simple enough let me know and I can maybe write it a different way.
    I hope LMTX can destroy tau tangles in humans, but to date there is no imaging evidence I have seen. Please post the info.
    Tanzi has demonstrated with his 3D human AD cell model that both AB and tangles are important.

    Sentiment: Strong Buy

  • Reply to

    Looking for a 10 bagger

    by kadaicher1 Jun 28, 2016 10:13 AM
    kadaicher1 kadaicher1 Jul 11, 2016 10:15 AM Flag

    One thing it is never boring, except for the rare occasions I read any of coppers posts:-)

    Sentiment: Strong Buy

  • Reply to

    Embargo, Embargo, I love you, Embargo

    by esoteric687 Jun 30, 2016 7:51 AM
    kadaicher1 kadaicher1 Jul 9, 2016 2:35 AM Flag

    Can Prana handle the pressure of a P3 trial? Ask board member Ira Shoulson. He has been instrumental in bringing several movement disorder drugs through P3 and FDA approval.

    Sentiment: Strong Buy

  • kadaicher1 kadaicher1 Jul 9, 2016 2:27 AM Flag

    LMTX is the second drug to target Tau. It has been known now for many years that PBT2 not only can break up tau tangles, but that through other arms of of the PBT2 MOA it also protects the microtubules from the hyperphosphorylation which leads to tau tangles.
    "Summary of new data presented at the 11th International Conference on Alzheimer’s and Parkinson’s Disease

    Melbourne – 8th March, 2013 Prana Biotechnology (NASDAQ:PRAN; ASX:PBT). Following on from the announcement released on 4th March, 2013 and at the request of the Australian Securities Exchange, the company is pleased to provide further detail in respect to the presentation of the new data demonstrating the ability of PBT2 to reduce the damage to brain cells, caused by the accumulation of the tau protein and preventing subsequent cognitive impairment.

    The data was generated in an animal model that over produces the tau protein giving rise to ‘tangle like’ inclusions similar to those which cause neuronal death in Alzheimer’s disease (AD). Importantly, whilst the anti-aggregation effects of PBT2 on Abeta have been well documented1, these results were generated in a model which is independent of the presence of Abeta, indicating that PBT2 has the ability to prevent neuronal damage via multiple metal mediated pathways, including Abeta and tau aggregation.

    The data is being presented by Prana scientist Associate Professor Paul Adlard on 9th March 2013 in his presentation entitled, “Metal Chaperones are novel therapeutic agents for tauopathy”.
    Copper, take note Adlard runs a lab at the Florey.

    Sentiment: Strong Buy

  • kadaicher1 kadaicher1 Jul 8, 2016 11:53 AM Flag

    Thats right, time to accumulate before this gets too expensive.

    Sentiment: Strong Buy

PRAN
4.39+0.04(+0.92%)Jul 22 3:57 PMEDT